Lupus Nephritis CRO Services

Tell us about your study

We’ll connect you with the right rare nephrology clinical development team.

The Team Behind the First FDA-Approved Oral Therapy for Adult Lupus Nephritis 

At Worldwide, we treat enrollment timing in lupus nephritis as a function of protocol design and patient access, not site count alone. With experience across pivotal programs in 30 countries and over 240 sites, we leverage early flare detection, centralized pathology review, and language-matched referral coordination to identify eligible patients sooner and keep recruitment on track in competitive study environments.

Narrow Eligibility Windows

Lupus nephritis flares are episodic and patients often feel well between them. The window in which a patient is both eligible and reachable can close before a site knows.

Diagnostic Consistency Across Sites

Biopsy interpretation, serological criteria, and eligibility documentation vary across global sites, and that variability surfaces at endpoint analysis rather than at trial entry.

Patient Populations Outside Traditional Trial Geographies

Lupus nephritis concentrates in populations outside North America and Western Europe, which puts referral coordination, language and travel logistics on the critical path rather than at the margins.

Senior Partnership Across the Life of the Lupus Nephritis Program

We ensure our Sponsors have easy access to senior scientific, medical, and project leaders who co-chair our renal portfolio and are empowered to make decisions without unnecessary escalation. For lupus nephritis programs, where every enrollment opportunity depends on flare timing and diagnostic precision, having the same experienced leaders involved from strategy through execution preserves momentum, reduces operational friction, and keeps programs moving forward.

What Worldwide’s Lupus Nephritis Programs Have Delivered

A pivotal Phase III delivered on time in a crowded recruitment field, through natural disasters that compromised site performance mid-study.

Enrollment Designed Around Disease Activity

Early Flare Detection & Enrollment Timing

Urine dipsticks for patient self-monitoring, disease surveillance and pre-screening chart review surface eligible patients while the enrolment window is open, supporting treatment initiation at symptom onset.

Central Pathology & Diagnostic Accuracy

Biopsy interpretation and eligibility documentation reviewed centrally across light microscopy, electron microscopy and immunofluorescence, so the trial-entry diagnosis holds through regulatory submission.

Global Patient Access & Travel Coordination

International patient travel and pre-qualification handled by language-matched, medically trained coordinators, alongside home health, concierge travel and patient navigator services. 

Your Questions Answered

We have answered the questions sponsors ask most often about lupus nephritis programs. If yours isn’t here, our rare nephrology team is happy to help.

In lupus nephritis, recruitment depends on finding patients while the enrollment window is still open. Because patients often feel well between flares, those opportunities can be missed until disease activity escalates and urgent care is required. Through proactive disease surveillance, patient education programs, and home urine dipstick monitoring for proteinuria, we help surface eligible patients earlier, connecting patients with care while they remain eligible and before disease progression leads to emergency intervention.

Central pathology review is integrated at the protocol level, covering light microscopy, electron microscopy, and immunofluorescence. Biopsy interpretation and eligibility documentation are managed consistently across every site and country, so the trial-entry diagnosis holds through regulatory submission. In an indication where classification drives both eligibility and the primary endpoint, that consistency is what protects the analysis.

Lupus nephritis populations concentrate outside North America and Western Europe. Worldwide coordinates international patient travel and pre-qualification through language-matched, medically trained coordinators, so referrals arrive at screening without language or logistics slowing them down. Home health, concierge travel and patient navigator services sit alongside that for patients traveling long distances.

Yes. On the pivotal Phase III lupus nephritis study, natural disasters threatened site participation mid-trial. Trial-naive sites were identified, trained and activated quickly to replace compromised capacity, enrollment was met ahead of schedule and database lock was delivered on time.

24-hour and first morning void collections carry much of the dropout risk in renal trials. We support them with non-spoken instructional videos, male and female collection containers, cooler backpacks for confidential transport, and at-home sample pickup where it can be arranged, alongside home health and patient navigator services.

Active comparators have replaced placebo controls in most new lupus nephritis programs, and proteinuria reduction is an accepted accelerated approval surrogate with eGFR slope confirming over 24 months. Endpoint strategy, designation opportunities and KOL engagement go into protocol design from the start rather than after the first regulatory meeting.